Andrew Cunningham
Technik-/Wissenschafts-/F&E-Leiter bei CALCIMEDICA, INC.
Profil
Andrew Cunningham is currently the Senior Vice President-Clinical Development at CalciMedica, Inc. He previously worked as the Medical Director at Takeda Pharmaceutical Co., Ltd.
from 2017 to 2018, and as the Medical Director at Genzyme Therapeutics Ltd.
from 2012 to 2014.
He also served as the Vice President-Clinical Development at Reata Pharmaceuticals, Inc. from 2018 to 2021, and as the Head-Neurodegenerative at Taysha Gene Therapies, Inc. from 2021 to 2022.
Dr. Cunningham obtained his undergraduate degree and an MBA from University College Dublin.
Aktive Positionen von Andrew Cunningham
| Unternehmen | Position | Beginn |
|---|---|---|
| CALCIMEDICA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.05.2023 |
Ehemalige bekannte Positionen von Andrew Cunningham
| Unternehmen | Position | Ende |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 01.04.2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.02.2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01.07.2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Andrew Cunningham
| University College Dublin | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| CALCIMEDICA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
